# Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection

> **NCT04251871** · NA · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Pneumonia Caused by Human Coronavirus (Disorder)

## Interventions

- **DRUG:** Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules
- **DRUG:** Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)

## Key facts

- **NCT ID:** NCT04251871
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-22
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-01-22
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251871, "Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04251871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*